Arcturus Therapeutics to Attend the Following Investor Conferences

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced its participation in upcoming investor conferences. The company will attend the Jefferies Cell and Genetic Medicine Summit from September 29 to 30, 2022, and present at the Cantor Neurology & Psychiatry Conference on October 6, 2022, at 2:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. To learn more, visit their website.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.

Jefferies Cell and Genetic Medicine Summit (Attending)

• Thursday – Friday, September 29 – 30, 2022

Cantor Neurology & Psychiatry Conference (Panel Presentation)

• Thursday, October 6, 2022 (2:30 – 3:30 p.m. ET)

If available, links can be found under the Investor Relations/Events section of the Arcturus’ website.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. In addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927006121/en/

IR and Media Contacts

Arcturus Therapeutics

IR@arcturusrx.com



Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

What investor conferences is Arcturus Therapeutics participating in?

Arcturus Therapeutics will attend the Jefferies Cell and Genetic Medicine Summit on September 29-30, 2022, and present at the Cantor Neurology & Psychiatry Conference on October 6, 2022.

What is the date of the Cantor Neurology & Psychiatry Conference presentation by Arcturus?

The presentation by Arcturus Therapeutics at the Cantor Neurology & Psychiatry Conference is scheduled for October 6, 2022, at 2:30 p.m. ET.

Where can I find more information about Arcturus Therapeutics events?

Additional information regarding Arcturus Therapeutics events can be found on their Investor Relations page on their official website.

What is Arcturus Therapeutics focused on developing?

Arcturus Therapeutics is focused on the development of mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases.